Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 12/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.46 |
| ▸ | CASP1 | P29466 | 3/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | CASP9 | P55211 | 2/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | CTSD | P07339 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | FURIN | P09958 | 1/20 | 0.40 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13194679 | 0.93 | CASP1 (0.50) | TASP1BACE1BACE2CASP1CASP3 | |
| SCHEMBL29310042 | 0.93 | CASP1 (0.50) | TASP1BACE1BACE2CASP1CASP3 | |
| SCHEMBL1674857 | 0.93 | CASP1 (0.50) | TASP1BACE1BACE2CASP1CASP3 | |
| SCHEMBL4100803 | 0.93 | CASP1 (0.50) | TASP1BACE1BACE2CASP1CASP3 | |
| SCHEMBL10068454 | 0.93 | CASP1 (0.47) | TASP1BACE1BACE2CASP1CASP3 | |
| SCHEMBL29946268 | 0.93 | TASP1 (0.51) | TASP1BACE1BACE2CASP1PTPN1 | |
| SCHEMBL29664764 | 0.88 | TASP1 (0.56) | TASP1BACE1BACE2CASP1CASP3 | |
| SCHEMBL20257263 | 0.87 | TASP1 (0.53) | TASP1CASP1CASP3CASP9CASP7 | |
| SCHEMBL20257260 | 0.87 | TASP1 (0.53) | TASP1CASP1CASP3CASP9CASP7 | |
| SCHEMBL29802241 | 0.86 | BACE1 (0.53) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-05-08 | — | — | US | disclosed |
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2025-04-17 | — | — | US | disclosed |
| US-12139744-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2024-11-12 | — | — | US | disclosed |
| US-12133720-B2 | Methods and compositions for restoring homeostatic capacity of a subject | Palo Alto Investors LP (US) | 2024-11-05 | — | — | US | disclosed |
| US-12110533-B2 | Stabilisation and isolation of extracellular nucleic acids | QIAGEN GMBH (DE) | 2024-10-08 | — | — | US | disclosed |
| US-20240287574-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | QIAGEN GMBH (DE) | 2024-08-29 | — | — | US | disclosed |
| EP-4397770-A1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PreAnalytiX GmbH (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3401406-B1 | STABILISATION AND ISOLATION OF EXTRACELLULAR NUCLEIC ACIDS | PREANALYTIX GMBH (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-11525155-B2 | Stabilisation of biological samples | QIAGEN GMBH (DE) | 2022-12-13 | — | — | US | disclosed |
| US-20220364149-A1 | STABILISATION OF BIOLOGICAL SAMPLES | QIAGEN GMBH (DE) | 2022-11-17 | — | — | US | disclosed |
| WO-2022190064-A1 | METHODS FOR IDENTIFYING SUBJECTS WITH BETACORONAVIRUS INFECTIONS WHO ARE AT RISK OF ACUTE RESPIRATORY SYNDROME AND METHODS FOR THE TREATMENT OF SAME | VEXO PHARMACEUTICALS DMCC (AE) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122555-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | TASP1 4313/4885BACE1 2824/4885BACE2 1807/4885 |
| US-12139744-B2 | Stabilisation of biological samples | RNASE1, RNASEH1, EWSR1 | TASP1 4313/4885BACE1 2824/4885BACE2 1807/4885 |
| US-20250146050-A1 | STABILISATION OF BIOLOGICAL SAMPLES | RNASE1, RNASEH1, EWSR1 | TASP1 4313/4885BACE1 2824/4885BACE2 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.